Avalo Therapeutics’ (AVTX) Neutral Rating Reiterated at Guggenheim

Guggenheim reissued their neutral rating on shares of Avalo Therapeutics (NASDAQ:AVTX) in a report published on Friday, MarketBeat reports.

A number of other brokerages have also recently weighed in on AVTX. Leerink Partners began coverage on shares of Avalo Therapeutics in a report on Monday, July 6th. They set an “outperform” rating and a $38.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Avalo Therapeutics in a report on Wednesday, September 16th. HC Wainwright reiterated a “neutral” rating on shares of Avalo Therapeutics in a research report on Friday. Weiss Ratings upgraded Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Wall Street Zen lowered Avalo Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 12th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $39.10.

Avalo Therapeutics Price Performance

Shares of AVTX opened at $6.93 on Friday. The firm’s 50 day moving average is $16.05 and its 200-day moving average is $16.61. The stock has a market capitalization of $371.66 million, a P/E ratio of -1.59 and a beta of 0.68. Avalo Therapeutics has a 12-month low of $6.53 and a 12-month high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last released its earnings results on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). As a group, equities research analysts forecast that Avalo Therapeutics will post -2.95 EPS for the current fiscal year.

Insider Activity

In other news, CFO Christopher Sullivan sold 12,394 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total transaction of $202,394.02. Following the sale, the chief financial officer owned 39,900 shares in the company, valued at $651,567. The trade was a 23.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 23,258 shares of company stock worth $395,434 in the last quarter. 4.46% of the stock is owned by insiders.

Hedge Funds Weigh In On Avalo Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AVTX. Squarepoint Ops LLC grew its position in Avalo Therapeutics by 624.9% during the 2nd quarter. Squarepoint Ops LLC now owns 589,245 shares of the company’s stock worth $10,889,000 after purchasing an additional 507,960 shares in the last quarter. Seven Fleet Capital Management LP raised its stake in Avalo Therapeutics by 34.3% during the 2nd quarter. Seven Fleet Capital Management LP now owns 770,765 shares of the company’s stock valued at $14,244,000 after purchasing an additional 196,882 shares during the period. Braidwell LP purchased a new stake in shares of Avalo Therapeutics in the second quarter valued at $30,107,000. Wellington Management Group LLP purchased a new stake in shares of Avalo Therapeutics in the second quarter valued at $1,945,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Avalo Therapeutics in the second quarter valued at $1,897,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Trending Headlines about Avalo Therapeutics

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: Some analysts still see substantial upside. BTIG Research maintained a “buy” rating while setting a $10 price target, and Wedbush retained its “outperform” rating with a $22 target. Those targets imply meaningful potential appreciation from the recent trading level. BTIG Research recommendations Wedbush price target update
• Neutral Sentiment: Mixed analyst views remain. Guggenheim reaffirmed its “neutral” rating, while Wedbush’s decision to remain bullish provides some support despite its lower target. Guggenheim recommendations
• Neutral Sentiment: Trading was briefly halted under a limit-up/limit-down, or LULD, pause. The halt reflects heightened volatility but does not itself indicate a fundamental change in Avalo’s business.
• Negative Sentiment: AbbVie’s positive Phase 3 HS data appears to have weakened Avalo’s competitive position. Investors may view AbbVie’s results as increasing competition and reducing the perceived commercial opportunity for Avalo’s lead asset, resulting in selling pressure. AbbVie Phase 3 data article
• Negative Sentiment: Analyst sentiment has deteriorated. HC Wainwright downgraded Avalo from “buy” to “neutral,” while Wedbush reduced its price target from $34 to $22 despite keeping an “outperform” rating. The target reduction signals greater near-term uncertainty. HC Wainwright downgrade

About Avalo Therapeutics

Avalo Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research and development programs are intended to address conditions with significant unmet medical needs.

Avalo’s lead product candidate is AVTX-009, a fully human monoclonal antibody designed to inhibit interleukin-1 beta, an inflammatory cytokine involved in several immune-related disorders. The candidate is being evaluated for potential treatment of hidradenitis suppurativa, a chronic inflammatory skin disease, and other inflammatory conditions.

The company was formerly known as Cerecor Inc and adopted the Avalo Therapeutics name in 2021.